Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 227,741,294 papers from all fields of science
Search
Sign In
Create Free Account
Hypoxia-activated Prodrug TH-4000
Known as:
TH-4000
A proprietary, hypoxia-activated prodrug with potential antineoplastic activity. Upon administration, the hypoxia-activated prodrug TH-4000 is…
Expand
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
2 relations
PR610
Receptor Tyrosine Kinase Inhibition
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
Review
2015
Review
2015
Abstract 5358: The hypoxia-activated EGFR-TKI TH-4000 overcomes erlotinib-resistance in preclinical NSCLC models at plasma levels achieved in a Phase 1 clinical trial
A. Patterson
,
Shevan Silva
,
+9 authors
J. Smaill
2015
Corpus ID: 78871310
Clinical data indicate that mutant EGFR NSCLC is often heterozygous (PLoS ONE 2013; 8: e54170; PLoS ONE 2009; 4: e7464) and the…
Expand
2015
2015
The Hypoxia-Activated EGFR-TKI TH-4000: Preclinical Profile and Ongoing Clinical Studies in NSCLC, SCCHN, and SCCS
A. Patterson
,
Shevan Silva
,
+13 authors
J. Smaill
2015
Corpus ID: 74272695
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE